HIV-1 and the self-nonself connection: how to sleep with the enemy and be much better off.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  AIDS Reviews

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 18820718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

  2008cited by this paper
• Critical issues in mucosal immunity for HIV-1 vaccine development.

  2008cited by this paper
• HLA Homology within the C5 Domain Promotes Peptide Binding by HIV Type 1 gp120

  2008cited by this paper
• The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design

  2008cited by this paper
• A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

  2007cited by this paper
• Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

  2007cited by this paper
• Understanding the benign nature of SIV infection in natural hosts.

  2007cited by this paper
• In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers

  2007cited by this paper
• Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy

  2007cited by this paper
• CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms

  2007cited by this paper
• Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection

  2007cited by this paper
• An HIV vaccine--evolving concepts.

  2007cited by this paper
• Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data

  2007cited by this paper
• Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

  2007cited by this paper
• Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity

  2007cited by this paper
• The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1

  2007cited by this paper
• CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1

  2007cited by this paper
• Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody.

  2007cited by this paper
• Receptor editing in lymphocyte development and central tolerance

  2006cited by this paper
• Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

  2006cited by this paper
• Is autoimmunity a component of natural immunity to HIV?

  2006cited by this paper
• GlaxoSmithKline ends aplaviroc trials.

  2006cited by this paper
• AIDS Res Hum Retroviruses

  2006cited by this paper
• Medicinal chemistry: Best of both worlds?

  2005cited by this paper
• Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells

  2005cited by this paper
• Antigenic complementarity between HIV and other AIDS-associated infections results in idiotype-antiidiotype antibody complexes that cross react with lymphocyte proteins.

  2005cited by this paper
• Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.

  2005cited by this paper
• Macrophages and HIV-1: dangerous liaisons.

  2005cited by this paper
• Clinical experience with therapeutic AIDS vaccines

  2005cited by this paper
• Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy

  2005cited by this paper
• Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

  2005cited by this paper
• Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

  2005cited by this paper
• Natural Antibodies to CCR5 from Breast Milk Block Infection of Macrophages and Dendritic Cells with Primary R5-Tropic HIV-11

  2005cited by this paper
• What's New in HIV/AIDS? Neutralizing HIV Antibodies: Do they Really Protect?

  2005cited by this paper
• Antibody polyspecificity and neutralization of HIV-1: A hypothesis

  2005cited by this paper
• Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1

  2005cited by this paper
• Factors regulating endogenous retroviral sequences in human and mouse

  2004cited by this paper
• Sex, alloimmunisation, and susceptibility to HIV infection.

  2004cited by this paper
• Retrovirus budding.

  2004cited by this paper
• CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection.

  2004cited by this paper
• Unprotected sex and alloimmune activation.

  2004cited by this paper
• Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection.

  2004cited by this paper
• Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance?

  2004cited by this paper
• Autoimmunity, anergy, lentiviral immunity and disease.

  2004cited by this paper
• CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects.

  2004cited by this paper
• HIV-1 Entry into T-cells Is Not Dependent on CD4 and CCR5 Localization to Sphingolipid-enriched, Detergent-resistant, Raft Membrane Domains*

  2003cited by this paper
• Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition

  2003cited by this paper
• Antibody neutralization and escape by HIV-1

  2003cited by this paper
• Assessing Human Alloimmunization as a Strategy for Inducing HIV Type 1 Neutralizing Anti-HLA Responses

  2003cited by this paper
• Positive and negative selection of T cells.

  2003cited by this paper
• The Trojan exosome hypothesis

  2003cited by this paper
• Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.

  2002cited by this paper
• HIV and autoimmunity.

  2002cited by this paper
• Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles

  2002cited by this paper
• Chemokines in autoimmunity: from pathology to therapeutics.

  2002cited by this paper
• Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection

  2002cited by this paper
• Allo‐immunization elicits CCR5 antibodies, SDF‐1 chemokines, and CD8‐suppressor factors that inhibit transmission of R5 and X4 HIV‐1 in women

  2002cited by this paper
• HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

  2002cited by this paper
• Distribution of HERV-LTR elements in the 5′-flanking region of HLA-DQB1 and association with autoimmunity

  2001cited by this paper
• Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

  2001cited by this paper
• On the relationship between viral infection and autoimmunity.

  2001cited by this paper
• CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro1

  2000cited by this paper
• Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients.

  2000cited by this paper
• Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.

  2000cited by this paper
• Evidence for Budding of Human Immunodeficiency Virus Type 1 Selectively from Glycolipid-Enriched Membrane Lipid Rafts

  2000cited by this paper
• Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5

  2000cited by this paper
• Progression of autoimmune thyroiditis in an HIV-infected woman on HAART.

  1999cited by this paper
• Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

  1999cited by this paper
• Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study

  1999cited by this paper
• Molecular Characterization of Dendritic Cell-Derived Exosomes

  1999cited by this paper
• Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission.

  1998cited by this paper
• Natural and disease associated autoantibodies to the autoantigen, dihydrolipoamide acetyltransferase, recognise different epitopes.

  1998cited by this paper
• The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies.

  1998cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Changes in thymic function with age and during the treatment of HIV infection

  1998cited by this paper
• Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Human Immunodeficiency Virus Type 1 Glycoprotein 120-Specific T Lymphocytes Provide Intermolecular Help for Anti-CD4 Autoantibody Production in Exposed Uninfected Subjects

  1997cited by this paper
• Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals

  1997cited by this paper
• The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity

  1997cited by this paper
• The Potential Roles of Endogenous Retroviruses in Autoimmunity

  1996cited by this paper
• Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals

  1996cited by this paper
• Epitope Specificity of Anti-HIV Antibodies in Human and Murine Autoimmune Diseases

  1996cited by this paper
• Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope.

  1996cited by this paper
• Human autoantibody recognition of DNA.

  1995cited by this paper
• Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1.

  1995cited by this paper
• Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals.

  1995cited by this paper
• Autoantibodies to the alpha/beta T-cell receptors in human immunodeficiency virus infection: dysregulation and mimicry.

  1994cited by this paper
• Human Antibodies to Immunodominant C5 Region of HIV-1 gp120 Cross-React with HLA Class I on Activated Cells

  1994cited by this paper
• Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations.

  1994cited by this paper
• Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study.

  1993cited by this paper
• Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients.

  1993cited by this paper
• Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I α1 peptide‐binding domain

  1993cited by this paper
• Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects.

  1993cited by this paper
• Endogenous retroviruses: potential etiologic agents in autoimmunity

  1992cited by this paper
• Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient.

  1991cited by this paper
• Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum.

  1990cited by this paper
• A population of murine hematopoietic progenitors expresses an endogenous retroviral gp70 linked to the Rmcf gene and associated with resistance to erythroleukemia

  1989cited by this paper
• Nonrandom association of cellular antigens with HTLV-III virions.

  1987cited by this paper

• Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies

  2017cites this paper
• Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women

  2012cites this paper
• FATTORI UMORALI PROTETTIVI COME STRUMENTI PER LA GENERAZIONE DI VACCINI EFFICACI CONTRO L'INFEZIONE DA HIV

  2011cites this paper
• HIV and the Sharpen Edge Between Protective and Pathogenic Immune Responses to the CD4 Self Antigen

  2010cites this paper
• Establishment and characterization of dengue virus type 2 nonstructural protein 1 specific T cell lines.

  2010cites this paper
• Journal of Translational Medicine Protective versus Pathogenic Anti-cd4 Immunity: Insights from the Study of Natural Resistance to Hiv Infection

  2009cites this paper